Inozyme Pharma's core business segment revolves around the development of therapeutics for rare diseases, particularly those related to defects in the phosphate, pyrophosphate, and calcium (PPC) axis. The company's primary focus is on addressing diseases impacting bone health, blood vessel function, and soft tissue mineralization. Research and development efforts are concentrated on understanding the underlying genetic and biochemical mechanisms of these rare conditions to identify novel therapeutic targets. The lead product candidate, INZ-701, is a soluble, recombinant protein designed to restore normal PPC balance and prevent abnormal mineralization. Clinical trials are underway to evaluate the safety and efficacy of INZ-701 in patients with ENPP1 deficiency, ABCC6 deficiency, and calciphylaxis. The company aims to provide innovative treatments that improve the quality of life for individuals affected by these debilitating rare diseases.